IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.6% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 10,400 shares of the company’s stock after selling 500 shares during the period. Louisiana State Employees Retirement System’s holdings in IDEXX Laboratories were worth $4,300,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the business. FSA Wealth Management LLC bought a new position in IDEXX Laboratories during the 3rd quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. grew its position in shares of IDEXX Laboratories by 5,700.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after acquiring an additional 57 shares during the last quarter. Mowery & Schoenfeld Wealth Management LLC grew its position in shares of IDEXX Laboratories by 750.0% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after acquiring an additional 60 shares during the last quarter. Ashton Thomas Securities LLC acquired a new stake in shares of IDEXX Laboratories in the 3rd quarter worth about $37,000. Finally, Retirement Wealth Solutions LLC bought a new stake in IDEXX Laboratories in the 4th quarter valued at about $31,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $457.35 on Thursday. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $583.39. The company has a current ratio of 1.31, a quick ratio of 1.03 and a debt-to-equity ratio of 0.28. The stock has a market cap of $37.45 billion, a PE ratio of 42.86, a price-to-earnings-growth ratio of 3.47 and a beta of 1.37. The company’s 50-day moving average price is $429.67 and its two-hundred day moving average price is $453.23.

Insider Transactions at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares in the company, valued at $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 13,330 shares of company stock valued at $6,161,276 in the last quarter. Insiders own 2.11% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Bank of America raised their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. Barclays raised their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, February 5th. Piper Sandler raised their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday. Finally, Morgan Stanley cut their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.